Zai Lab Ltd
HKEX:9688
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
10.62
25.65
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Zai Lab Ltd stock under the Base Case scenario is 29.06 HKD. Compared to the current market price of 19.76 HKD, Zai Lab Ltd is Undervalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zai Lab Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Zai Lab Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Zai Lab Ltd
Balance Sheet Decomposition
Zai Lab Ltd
Current Assets | 860.5m |
Cash & Short-Term Investments | 616.1m |
Receivables | 69.2m |
Other Current Assets | 175.2m |
Non-Current Assets | 124.8m |
Long-Term Investments | 3.2m |
PP&E | 63.6m |
Intangibles | 54.7m |
Other Non-Current Assets | 3.4m |
Current Liabilities | 286.3m |
Accounts Payable | 120.7m |
Accrued Liabilities | 46.3m |
Short-Term Debt | 113m |
Other Current Liabilities | 6.4m |
Non-Current Liabilities | 31.4m |
Other Non-Current Liabilities | 31.4m |
Earnings Waterfall
Zai Lab Ltd
Revenue
|
355.7m
USD
|
Cost of Revenue
|
-130.3m
USD
|
Gross Profit
|
225.4m
USD
|
Operating Expenses
|
-562.9m
USD
|
Operating Income
|
-337.5m
USD
|
Other Expenses
|
66.7m
USD
|
Net Income
|
-270.8m
USD
|
Free Cash Flow Analysis
Zai Lab Ltd
USD | |
Free Cash Flow | USD |
In the third quarter of 2024, Zai Lab's net product revenue surged 47% to $101.8 million, driven by a remarkable increase in VYVGART sales, which reached $27.3 million from $4.9 million year-over-year. The company expects to exceed $80 million in VYVGART sales by year-end, reinforcing its path to profitability by late 2025. Key advancements include promising data for ZL-1310 in small cell lung cancer, boasting a 74% objective response rate. With a cash position of $716 million and multiple product launches anticipated, Zai Lab aims to leverage its expanding pipeline to achieve over $1 billion in sales potential for VYVGART in China.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
Zai Lab Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Zai Lab Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Zai Lab Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
Zai Lab Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Zai Lab Ltd
According to Wall Street analysts, the average 1-year price target for Zai Lab Ltd is 37.29 HKD with a low forecast of 15.15 HKD and a high forecast of 69.05 HKD.
Dividends
Current shareholder yield for Zai Lab Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zai Lab Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The firm is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The firm has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Contact
IPO
Employees
Officers
The intrinsic value of one Zai Lab Ltd stock under the Base Case scenario is 29.06 HKD.
Compared to the current market price of 19.76 HKD, Zai Lab Ltd is Undervalued by 32%.